MAP2K7 and hematopoietic and lymphoid cell neoplasm: Although previous literature has suggested potential utility of BET/MEK combinations in a few, specific settings6–11, our data show that combined BET and MEK inhibition is broadly synergistic across solid and hematologic cancer models.